Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Circulation. Author manuscript; available in PMC 2010 August 4.
Published in final edited form as:
PMCID: PMC2768575

Repair of acute myocardial infarction with iPS induced by human stemness factors



Nuclear reprogramming provides an emerging strategy to produce embryo-independent pluripotent stem cells from somatic tissue. Induced pluripotent stem cells (iPS) demonstrate aptitude for de novo cardiac differentiation, yet their potential for heart disease therapy has not been tested.

Methods and Results

Here, fibroblasts transduced with human stemness factors OCT3/4, SOX2, KLF4, and c-MYC converted into an embryonic stem cell-like phenotype and demonstrated the ability to spontaneously assimilate into preimplantation host morula via diploid aggregation, unique to bona fide pluripotent cells. In utero, iPS-derived chimera executed differentiation programs to construct normal heart parenchyma patterning. Within infarcted hearts in the adult, intramyocardial delivery of iPS yielded progeny that properly engrafted without disrupting cytoarchitecture in immunocompetent recipients. In contrast to parental non-reparative fibroblasts, iPS treatment restored post-ischemic contractile performance, ventricular wall thickness and electrical stability while achieving in situ regeneration of cardiac, smooth muscle and endothelial tissue.


Fibroblasts reprogrammed by human stemness factors thus acquire the potential to repair acute myocardial infarction, establishing iPS in the treatment of heart disease.

Keywords: transplantation, induced pluripotent stem cells, regenerative medicine

Regenerative medicine offers the potential of curative therapy to repair damaged tissues.1,2 Pluripotent stem cells derived from the inner cell mass of early stage embryos have provided a prototype for multi-lineage repair. Ethical considerations along with practical limitations have however precluded adoption of embryonic stem cell platforms, driving advances in nuclear reprogramming to establish viable alternatives.3 In this regard, induced pluripotent stem cell (iPS) technology provides an emerging innovation that promises the unlimited potential of embryonic stem cells while circumventing the need for embryonic sources.4

Nuclear reprogramming designed to convert somatic tissues into stem cells capable of germline transmission has been recently achieved with ectopic expression of various pluripotent gene combinations.5-8 Delivery of stemness-related gene sets, exemplified by the Oct-3/4, Sox2, Klf4 and c-Myc quartet,5 reprograms adult somatic cells by promoting re-acquisition of evolutionarily conserved embryonic gene networks.9 By reinstating pluripotency, iPS reset the biological age of a cell reflected in the re-lengthening of telomeres.10 The potential for reversing adult cell fates has been systematically exploited, producing iPS from diverse tissue origins across phylogenetic barriers.11,12

Although induced pluripotency reliably generates an embryonic-like ground state from healthy and diseased sources,13,14 the therapeutic value of reprogramming remains largely unknown. To date, only three disease models have been treated with iPS-derived strategies.15-17 Interventions in sickle cell anemia, Parkinson's disease, and hemophilia A have been limited to lineages pre-specified in vitro.15-17 Despite recapitulating the cardiomyogenic phenotype from both murine and human somatic fibroblasts,18-21 multi-lineage repair of heart tissue with iPS-based intervention has yet to be documented.

We here demonstrate for the first time the efficacy of iPS to treat acute myocardial infarction. Murine fibroblasts were transduced with human stemness-related factors through an efficient vector system to generate valid iPS clones with inherent cardiogenic potential. Head-to-head comparison between parental fibroblasts and reprogrammed progeny established the acquired propensity for cardiac tissue regeneration in a setting of ischemic heart disease. iPS progeny engrafted in the context of immunocompetent allogeneic transplantation, and rescued post-ischemic myocardial structure and function. This proof-of-principle study pioneers fibroblast-derived iPS in cardiac repair.


Protocols were approved by the Institutional Animal Care and Use Committee.


pSIN-CSGWdlNotI-derived transfer vectors were generated with human OCT3/4, SOX2, KLF4 and c-MYC cDNAs (Open Biosystems).22 The packaging plasmid, pCMVR8.91, was engineered with H87Q mutation in the HIV-1 capsid region for increased transduction efficiency of purified infectious supernatants.22 Mouse embryonic fibroblasts, obtained from embryos at 14.5 days post-coitum (dpc), were expanded in maintenance medium containing Dulbecco's modified Eagle's medium (Invitrogen) supplemented with 10% fetal calf serum (FCS), 1% L-glutamine (Invitrogen) and 1% penicillin/streptomycin, and plated at 105/24-wells prior to transduction for 12 h with infectious supernatants. Transduced fibroblasts were replated at confluence, and iPS isolated in 2 weeks for clonal expansion. Cells were labeled with HIV vectors carrying LacZ (pLenti6/UbC/V5-GW/LacZ, Invitrogen) or luciferase (pSIN-Luc).23

Pluripotent induction

R1-derived embryonic stem cells and iPS were expanded in embryonic stem cell media. Cells were fixed with 3% paraformaldehyde, permeabilized and stained with anti-SSEA-1 antibody (MAB4301; dilution 1:50; Chemicon) along with secondary goat anti-mouse Alexa Fluor 568 (1:250; Invitrogen). Nuclei were labeled with 4,6′-diamidino-2-phenylindole (DAPI; Invitrogen). For ultrastructural evaluation, cells were examined on Hitachi 4700 field emission scanning or JEOL 1200 EXII transmission electron microscopes.24 Growth and differentiation potential were determined upon subcutaneous injection in anesthetized (2-3% isoflurane) athymic nude mice. Cryopreserved tissue was processed for hematoxylin/eosin procedures.25,26


iPS were differentiated into embryoid bodies using the hanging-drop method.27 Expression of pre-cardiac mesoderm and cardiac differentiation markers was detected by RT-PCR. Total RNA was extracted with a combination of gDNA Eliminator and RNeasy columns (Qiagen). cDNA was prepared from RNA samples using Superscript III First Strand Synthesis System (Invitrogen). Mouse Gapdh (4352932E; Applied Biosystems) was used as control. Analyzed genes included Gata4 (Mm00484689_m1), Myocd (Mm00455051_m1), and Mef2c (Mm01340839_m1; Applied Biosystems).

Diploid aggregation

Contribution to embryonic development was assessed through diploid aggregation.28 Host embryos from CD-1 superovulated females were collected at 2.5 dpc. Fibroblasts or iPS were partially digested using trypsin 0.25%-EDTA (Invitrogen), and 8-15 cell clumps were placed with paired embryos denuded of zona pellucida. The aggregation complex was incubated for 24 h (in 5% CO2/5% O2/90% N2) until blastocyst cavitation.28 Chimeric embryos were transplanted into anesthetized (2-3% isoflurane) pseudopregnant surrogate CD-1 mothers, harvested at 9.5 dpc, and analyzed for distribution of LacZ-labeled progenitors.28

iPS therapy

Male, 8-12 weeks old C57BL/6 or athymic nude mice were anesthetized (1.5-2% isoflurane), intubated (Mini Vent 845, Hugo Sacks Electronik), and left coronary artery ligated with a 9-0 suture under direct visualization following minimally invasive thoracotomy. Myocardial ischemia was confirmed by electrocardiography, echocardiography, and color change of left ventricular wall. Fibroblasts or iPS (200,000/10 μl of differentiation medium) were transplanted with four injections of 2.5 μl within 30 min after ligation. Cryosections (7 μm-thickness) were processed for hematoxylin/eosin, Masson's trichrome, luciferase and β-gal staining.25,26 Sections were labeled with luciferase (1:5000, Sigma) or β-galactosidase antibody (1:5000, Abcam) coupled with Alexa-568 secondary antibody (1:1000, Invitrogen) and co-localized with α-actinin (1:200, Sigma), smooth muscle actin (1:200, Abcam), CD31 (1:200, Abcam), or SSEA-1 (1:50, Chemicon) antibodies all paired with Alexa-488 antibody (1:1000, Invitrogen).

Live cell imaging and heart performance

Luciferase-transfected fibroblasts or iPS were cultured for multiple passages including a freeze/thaw cycle prior to expansion and transplantation. Cells were tracked with the IVIS 200 Bioluminescence Imaging System (Xenogen) following intra-peritoneal injection of 150 mg/kg D-luciferin (Xenogen), and signals analyzed with the Living Image Software (Xenogen). Ventricular performance was quantified by echocardiography (RMV-707B scanhead, Vevo770, Visual Sonics). Ejection fraction (%) was calculated as [(LVVd - LVVs)/LVVd] × 100, where LVVd is left ventricular end-diastolic volume (μL) and LVVs, left ventricular end-systolic volume (μL). Left ventricular fractional shortening (% FS) was calculated as [(LVDd - LVDs)/LVDd] × 100, where LVDd is left ventricular end-diastolic dimension (mm) and LVDs, left ventricular end-systolic dimension (mm).25 Electrical activity was monitored by electrocardiography (MP150, Biopac). Data was collected and analyzed by blinded investigators.

Statistical analysis

Results are presented as mean±SEM. Median is additionally reported when grouped data were compared with nonparametric Mann-Whitney U test. Comparison between groups over time was performed by two-way repeated-measures ANOVA. Kaplan-Meier analysis was applied with log-rank testing. p<0.05 was predetermined as significant, and all values >0.001 were reported.


Nuclear reprogramming resets primitive morphology and unlocks functional pluripotency

Transduced with human stemness factors, OCT3/4, KLF4, SOX2 and c-MYC, reprogrammed fibroblasts were isolated according to compact clusters of embryonic stem cell-like morphology distinct from monomorphic, single-cell layers of parental fibroblasts (Figure 1A). Reprogrammed cells displayed distinct sub-cellular architecture, reorganized from original fibroblasts to recapitulate salient features of undifferentiated embryonic stem cells with high nucleo/cytoplasmic ratio, predominance of nuclear euchromatin and scant density of cytosolic organelles (Figure 1B). Reprogramming induced expression of the early embryonic SSEA-1 antigen, an initial marker of stemness absent in parental fibroblasts (Figure 1C). To determine functional pluripotency, the inherent capacity for embryonic integration was probed by diploid aggregation using a pair of denuded host embryos (Figure 1D, upper). While morula-derived blastomeres incorporated into an embryonic structure after 24 h in micro-wells, fibroblasts aborted engraftment and failed to contribute to ex utero blastocyst development (Figure 1D, lower left). In contrast, reprogrammed fibroblasts demonstrated spontaneous integration and contributed to pre-implantation blastocyst formation (Figure 1D, lower right). Non-coerced assimilation into early stage embryos thereby established bona fide iPS clones, providing a high-stringency quality control measure for functional pluripotency.

Figure 1
Induced pluripotent stem cells (iPS) demonstrate pluripotent features. A, Flat fibroblasts reprogrammed with human stemness factors metamorphosed into rounded clusters shown by field-emission scanning electron microscopy. Bar=50 μm. B, In transmission ...

Chimeric embryos authenticate iPS-derived patterning of normal cardiogenesis

As iPS differentiated within 5-day-old embryoid bodies (Figure 2A), up-regulation of pre-cardiac markers Mesp1, Tbx5, Cxcr4, and Flk-1 indicated engagement beyond the original fibroblast lineage29,30 (not illustrated). Within 12 days, increased expression of canonical cardiac transcription factors, Mef2c (p=0.049; n=3), Gata4 (p=0.049; n=3) and Myocardin (p=0.049; n=3), indicated the capacity for cardiac tissue maturation (Figure 2B). Beyond redirection of somatic cell fate in vitro, chimeric embryos were utilized to examine the ability of iPS clones to ensure tissue formation during embryonic development in utero. Pre-implantation blastocysts containing lacZ-labeled iPS progenitors were transferred into surrogate uterus, and tracked at early stages of organogenesis. iPS labeled with a constitutively active reporter construct mimicked the stochastic distribution of embryonic stem cells throughout the developing embryo at 9.5 dpc (Figure 2C). Labeled iPS progeny demonstrated robust contribution to the heart field, including cardiac inflow and outflow tracts as well as left and right ventricles of the embryonic heart parenchyma (Figure 2D and 2E). Thereby, qualified iPS clones demonstrated de novo organogenesis and patterning of cardiogenic tissue within a developing embryo.

Figure 2
iPS recapitulate in utero cardiogenic propensity. A, LacZ-labeled iPS clones, detected by β-galactosidase (β-gal) staining, were maintained as undifferentiated colonies at day 0 before aggregation into embryoid bodies (EB). B, Gene expression ...

iPS engraft into infarcted immunocompetent adult hearts

In contrast to fibroblasts unable to proliferate even after prolonged incubation, subcutaneous injection of iPS clones within an immunodeficient adult environment demonstrated aggressive growth (Figure 3A). Transplanted cells, initially labeled with retroviral reporter constructs and expanded through multiple passages (>5) in vitro, were tracked with in vivo imaging using emitted bioluminescence from iPS-derived progeny. Upon permanent occlusion of epicardial coronary vasculature and microsurgical transfer into the ischemic myocardium, iPS remained within injected hearts and produced gradual tumor outgrowth between 2-4 weeks (Figure 3B). Echocardiography confirmed a significant tumor burden, which compromised hemodynamics 4-weeks post-transplant (Figure 3C). Autopsy in immunodeficient recipients (n=6) verified consistent teratoma formation with extension beyond the myocardial wall and tumor infiltration within the post-injured myocardium (Figure 3C). In contrast to tumorigenesis that compromised the safety within immunodeficient environments, subcutaneous transplantation of iPS into immunocompetent hosts demonstrated a persistent absence of tumor growth in all animals (n=6) even at 8 weeks of follow-up (Figure 3D). Furthermore, intramyocardial transplantation of 200,000 iPS/heart, a dose selected based on tumor-free outcome with embryonic stem cell intervention,26,27 produced stable engraftment without detectable tumor formation (n=6; Figure 3E). According to bioluminescence emitted from labeled progeny, differentiated iPS within ischemic immunocompetent hearts were detectable by 2 weeks post-transplantation without metastatic dissemination after 4 weeks of engraftment (n=6; Figure 3E). In fact, immunostaining of hearts at 4 weeks demonstrated rare iPS progeny positive for SSEA-1 expression within the post-ischemic myocardium (Figure 3F). Immunocompetent recipients thus ensured controlled iPS engraftment (Figure 3G) with tissue integration that did not perturb electrical homeostasis (n=6; Figure 3H). In this way, the immunocompetent adult host provided a permissive environment for differentiation, offering the opportunity to test the therapeutic potential of iPS clones.

Figure 3
iPS fate determined by host competency. A, Subcutaneous injection of 500,000 iPS in immunodeficient host resulted in tumor growth (dotted circle). B, Upon acute myocardial infarction, 200,000 iPS transplanted intra-myocardially were detected in the heart ...

iPS therapy restores myocardial performance lost by ischemic injury

Within immunocompetent hosts, recovery of post-ischemic cardiac performance was compared in randomized cohorts transplanted with parental fibroblasts versus derived iPS. Monitored by echocardiography, irreversible occlusion of the epicardial coronary blood flow consistently impaired anterior wall motion, depressed global cardiac function, and halved ejection fraction (EF) from 82±3% before infarction (n=8) to 38±3% within 1-day post-infarction (n=12; Figure 4A). While blinded transplantation with parental fibroblasts demonstrated persistent functional decline with EF dropping to 37±4% at 4 weeks (n=6), iPS intervention improved cardiac contractility to achieve an EF of 56±2% within the first 2-weeks of therapy and 50±5% by 4 weeks (n=6; p=0.002 iPS versus fibroblasts, Figure 4A). Functional benefit in response to iPS was verified by the improved fractional shortening, from 20±1% (median 18%, n=6) at 1-day post-infarction to 31±3% (median 29%, n=6) after 4-weeks, in contrast to a lack of recovery in fibroblast-treated hearts (n=6, p=0.01; Figure 4B). Moreover, the regional septal wall thickness in systole was significantly rebuilt with iPS (1.31±0.11 mm, median 1.20 mm, n=5), but not with fibroblast (0.88±0.06 mm, median 0.90 mm, n=6) treatment (p=0.006; Figure 4C). Impaired cardiac contractility in the injured anterior wall resulted in akinetic regions with paradoxical motion in systole indicative of aneurysms in fibroblast-treated hearts, in contrast to coordinated concentric contractions in response to iPS treatment visualized by long-axis and short-axis imaging (Figure 4D and 4E). Thus, compared to non-reparative parental fibroblasts, iPS intervention improved functional performance following acute myocardial infarction.

Figure 4
iPS restored function following acute myocardial infarction (MI). A, Upon randomization, cell-based intervention was performed at 30 min after coronary ligation. Divergent ejection fractions were noted in iPS (n=6) versus fibroblast (n=6) treated hearts ...

iPS therapy halts progression of pathologic remodeling in infarcted hearts

Beyond functional deterioration, maladaptive remodeling with detrimental structural changes prognosticates poor outcome following ischemic injury. Here, iPS-based intervention attenuated global left ventricular diastolic diameter (LVDd). Pre-infarction LVDd measured 3.2±0.1 mm (median 3.1 mm), but increased post-infarction to 4.9±0.1 mm (median 4.9 mm) by 4-weeks of fibroblast treatment (n=6) a value significantly higher (p=0.007) than 4.2±0.2 mm (median 4.2 mm) with iPS treatment (n=6; Figure 5A). Furthermore, echocardiography demonstrated regional structural deficits with deleterious wall thinning and chamber dilation in fibroblast-treated hearts (n=6), rescued by iPS intervention (n=6; Figure 5B). Pathologic structural remodeling leads to electrophysiological consequences with prolongation of the QT interval, which increases risk of arrhythmia. Infarction increased QT interval from 28.9±1.4 ms (median 28.1 ms) to 55.9±1.3 ms (median 55.8 ms) in fibroblast-treated hearts (n=6), which was abrogated to 40.8±1.5 ms (median 40.3 ms, n=6) with iPS treatment (p=0.004, Figure 5C). These real-time surrogates for tissue remodeling were confirmed on autopsy on inspection of gross specimen that demonstrated reduced heart size, lack of aneurysmal formation, and absence of severe wall thinning in iPS compared to fibroblast-treated hearts (Figure 5D). Collectively, the favorable remodeling at global, regional and electrical level demonstrates overall benefit of iPS therapy in the setting of myocardial infarction.

Figure 5
iPS halt maladaptive remodeling and preserve structure. A, Diastolic parameters revealed a significant decrease in global left ventricular diastolic diameter (LVDd) in hearts treated with iPS (n=6) compared to fibroblasts (n=6) at 4-weeks post-therapy ...

Multi-lineage cardiac tissue regeneration following iPS therapy

Histological analysis demarcated de-muscularization and extensive scarring within left ventricles distal to coronary ligation in hearts treated with fibroblasts 4 weeks following transplantation (Figure 6A). In contrast, iPS treatment halted structural deterioration of infarcted tissue with anti-fibrotic benefit and remuscularization within the left ventricular free wall (Figure 6A). Surgical dissection and postmortem histopathological analysis verified absence of tumor infiltration or dysregulated cell expansion following iPS transplantation in the myocardium itself, as well as in the liver, lung and spleen - organs with high metastatic risk (n>10 staggered sections throughout respective organs; Figure 6B). In post-ischemic myocardium, immunohistochemistry confirmed engraftment of iPS-derived progeny that expressed transgene markers luciferase (not illustrated) or β-galactosidase (Figure 6C-E). Co-localization of transgene expression with cardiac α-actinin was consistent within the damaged territory as documented by microscopy of serial transverse sections (n>10 at 10-20 μm intervals) immediately adjacent to the site of coronary ligation (Figure 6C). Smooth muscle α-actin (Figure 6D) and endothelial CD31 (Figure 6E) were also detectable, albeit at lower frequency, consistent with multi-lineage cardiovascular differentiation of iPS. Thus, in contrast to ineffective parental fibroblasts, targeted delivery of iPS generated de novo cardiovascular tissue in post-ischemic adult myocardium.

Figure 6
iPS treatment reduced scar and contributed to multi-lineage reconstruction. A, After 4 week of therapy, Masson's trichrome staining demonstrated reduced anterior wall thickness (AWT) and fibrosis (blue staining) in hearts treated with fibroblasts (left) ...


Nuclear reprogramming with iPS technology offers embryo-independent pluripotent progenitors. While enabling patient-specific regenerative platforms,31 prior to this study iPS have been limited to three non-cardiac disease conditions, namely sickle cell anemia, Parkinson's disease and hemophilia A.15-17 The present study expands the therapeutic indications of iPS by providing first evidence for repair in the context of heart disease.

The ability to reprogram somatic tissue and reactivate atavistic functions of pluripotency has forged a new strategy for regenerative biology.31-34 Somatic cell nuclear transfer provided the initial empiric evidence for epigenetic conversion of non-stem cells to acquire pluripotency.35 More recently, nuclear reprogramming has been induced with the minimal requirement of ectopic gene expression of stemness factors.36,37 High-stringency testing for bona fide pluripotency has been restricted to low-throughput procedures, such as germline transmission and tetraploid aggregation.6,7 Non-coerced diploid aggregation, presented here, offers a rapid yet reliable surrogate marker for functional pluripotency with definitive readout feasible within 24 h. Acquired pluripotency from somatic fibroblasts was herein verified by the inability of parental, non-reprogrammed counterparts to contribute to blastocyst development. As iPS technology continues to advance,36-38 diploid aggregation techniques offers thereby a high-throughput functional assay to screen for the pluripotent state of a clonal progenitor population.

Stem cell-based repair integrates multifactorial mechanisms with cardiac regeneration predicated on the ability of diseased myocardium to be replenished with healthy multi-lineage tissue.39-45 Rejuvenation can be achieved from endogenous stem cell pools that respond to injury, albeit at levels typically insufficient to compensate for severe cardiac damage.39 Exogenous stem cell types have been employed to augment therapeutic healing through paracrine mediated mechanisms40 and/or cell-autonomous contribution to tissue reconstruction.41,42 In this way, embryonic stem cells have reproduced the complete cellular repertoire within ischemic heart,43-45 and have demonstrated the ability to augment the physical force of cardiac contraction upon transplantation.45 The present study introduces iPS therapy into a diseased myocardium as an alternative to produce cardiogenic tissue independently of an embryonic source. The iPS platform for cell-based regeneration relies on the acquired ground state of pluripotency to enable somatic tissue-derived cardiopoiesis, here validated by in vitro differentiation with canonical cardiac transcription factor expression and in utero organogenesis with heart parenchyma patterning. Live-cell imaging documented in situ reconstruction of damaged tissues and engraftment of iPS-derived progeny within the heart, as transplanted cells were extensively processed to avoid carry-over of lentiviral particles that could cross-contaminate native tissue and confound analysis of in vivo cell tracking.46,47 Intramyocardial transplantation of parental fibroblasts within acutely infarcted tissue was unproductive, despite previous indications that a multitude of cell types may improve cardiac function.48 In contrast, iPS responded to cardiac injury with controlled integration and chimeric tissue formation within allogeneic host. Cell integration translated into performance recovery as qualified iPS clones contributed to tissue reconstruction with synchronized cardiovasculogenesis, composed predominantly of cardiac lineage with accompanying smooth muscle and endothelium. Although multiple mechanisms likely contribute to the benefit associated with iPS-based therapy, converting fibroblasts, main contributors to post-ischemic scar, into reparative progenitors can thus now be considered as a goal to engage and promote de novo tissue repair.

The heterogeneity inherent to the epigenetics and gene expression profiles within pluripotent cells raises however concern for pleiotropic outcomes.2,21,49 Both embryonic stem cells and iPS harbor the potential risk of producing teratoma. The propensity for uncontrolled growth of embryonic stem cells is nevertheless modulated by the immunity of non-native environment, as here demonstrated for iPS within adult immunocompetent hosts. A properly matched milieu, such as that of the developing embryo, furthermore ensures precise differentiation and in utero growth.28 Diploid aggregation, utilizing the chimeric environment, revealed the reliability of iPS clones to orchestrate tissue patterns without triggering tumorigenic outgrowth, in line with tumor-free organogenesis of iPS offspring.3,6,7 Fully differentiated cell types, such as native fibroblasts used here, are in contrast unable to contribute to primordial embryo or heart repair. Exemplified by the inability to integrate into the electrical syncytium of failing myocardium, transplantation of non-stem cell progeny has been plagued by the rigidity associated with advanced fate.48,50 Accordingly, the risk-benefit of iPS-based interventions will critically depend on the state of lineage differentiation and the interface with host milieu.

In conclusion, this study expands the therapeutic potential of iPS treatment from non-cardiac to cardiac disease. Created by ectopic expression of four human stemness related factors, iPS demonstrated acquired cardiogenicity, and ensured functional and structural repair of infarcted myocardium. While individual iPS clones are likely to exhibit a spectrum of reparative potential, advances in nuclear reprogramming provide the tools to customize the reversibility of cell fate for “on-demand” cardiovascular regenerative medicine.


We thank Jonathan Nesbitt for surgical expertise and Lois Rowe for histological analysis.

Funding Sources: Supported by National Institutes of Health (R01HL083439, T32HL007111, R01HL085208, R56AI074363), American Heart Association, American Society for Clinical Pharmacology and Therapeutics, National Hemophilia Foundation, La Caixa Foundation Graduate Program, Marriott Individualized Medicine Program, Marriott Heart Disease Research Program, and Mayo Foundation.


Disclosures: None

Triggered nuclear reprogramming through ectopic transgene expression of stemness factors offers a revolutionary strategy for embryo-independent derivation of pluripotent stem cells from an ordinary adult source. Induced pluripotent stem cell (iPS) technology invalidates chronological age, reversing cell fate to reset an atavistic embryonic-like potential of somatic tissue. In this way, iPS have attained functions previously demonstrated only by natural embryonic stem cells to independently produce all tissues types and develop the complete organism within an embryonic environment. Here, fibroblasts redirected by a foursome of human stemness factors, OCT3/4, SOX2, KLF4 and c-MYC, acquired bona fide pluripotent features ensuring de novo tissue replacement in embryonic and adult host environments. Head-to-head comparison between parental fibroblasts and reprogrammed progeny established the therapeutic value for cardiac tissue regeneration in a setting of ischemic heart disease. Specifically, transplantation of iPS in the acutely infarcted myocardium yielded structural and functional repair to secure performance recovery as qualified clones contributed to in vivo tissue reconstruction with “on-demand” cardiovasculogenesis. Although the full clinical impact of iPS-based technology will be revealed when safeguards are fully validated, the proof-of-principle study here establishes the practical application of bioengineered stem cells to respond to the ischemic myocardium and heal the damaged areas with iPS-derived integrated functional tissues. Therefore, converting self-derived fibroblasts, main contributors to post-ischemic scar, into reparative progenitors can now be considered as a goal of regenerative medicine to individualize treatment algorithms for multi-lineage cardiovascular repair.


1. Daley GQ, Scadden DT. Prospects for stem cell-based therapy. Cell. 2008;132:544–548. [PubMed]
2. Segers V, Lee RT. Stem-cell therapy for cardiac disease. Nature. 2008;451:937–942. [PubMed]
3. Yamanaka S. Strategies and new developments in the generation of patient-specific pluripotent stem cells. Cell Stem Cell. 2007;1:39–49. [PubMed]
4. Nishikawa S, Goldstein RA, Nierras CR. The promise of human induced pluripotent stem cells for research and therapy. Nat Rev Mol Cell Biol. 2008;9:725–729. [PubMed]
5. Takahashi K, Okita K, Nakagawa M, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126:663–676. [PubMed]
6. Okita K, Ichisaka T, Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nature. 2007;448:313–317. [PubMed]
7. Wernig M, Meissner A, Foreman R, Brambrink T, Ku M, Hochedlinger K, Bernstein BE, Jaenisch R. In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature. 2007;448:318–324. [PubMed]
8. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir GA, Ruotti V, Stewart R, Slukvin II, Thomson JA. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007;318:1917–1920. [PubMed]
9. Silva J, Barrandon O, Nichols J, Kawaguchi J, Theunissen TW, Smith A. Promotion of reprogramming to ground state pluripotency by signal inhibition. PLoS Biol. 2008;6:e253. [PMC free article] [PubMed]
10. Marion RM, Strati K, Li H, Tejera A, Schoeftner S, Ortega S, Serrano M, Blasco MA. Telomeres acquire embryonic stem cell characteristics in induced pluripotent stem cells. Cell Stem Cell. 2009;4:141–154. [PubMed]
11. Lowry WE, Plath K. The many ways to make an iPS cell. Nat Biotechnol. 2008;26:1246–1248. [PubMed]
12. Aoi T, Yae K, Nakagawa M, Ichisaka T, Okita K, Takahashi K, Chiba T, Yamanaka S. Generation of pluripotent stem cells from adult mouse liver and stomach cells. Science. 2008;321:699–702. [PubMed]
13. Ebert AD, Yu J, Rose FF, Jr, Mattis VB, Lorson CL, Thomson JA, Svendsen CN. Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature. 2009;457:277–280. [PMC free article] [PubMed]
14. Dimos JT, Rodolfa KT, Niakan KK, Weisenthal LM, Mitsumoto H, Chung W, Croft GF, Saphier G, Leibel R, Goland R, Wichterle H, Henderson CE, Eggan K. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science. 2008;321:1218–1221. [PubMed]
15. Hanna J, Wernig M, Markoulaki S, Sun CW, Meissner A, Cassady JP, Beard C, Brambrink T, Wu LC, Townes TM, Jaenisch R. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science. 2007;318:1920–1923. [PubMed]
16. Wernig M, Zhao JP, Pruszak J, Hedlund E, Fu D, Soldner F, Broccoli V, Constantine-Paton M, Isacson O, Jaenisch R. Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease. Proc Natl Acad Sci USA. 2008;105:5856–5861. [PubMed]
17. Xu D, Alipio Z, Fink LM, Adcock DM, Yang J, Ward DC, Ma Y. Phenotypic correction of murine hemophilia A using an iPS cell-based therapy. Proc Natl Acad Sci USA. 2009;106:808–813. [PubMed]
18. Schenke-Layland K, Rhodes KE, Angelis E, Butylkova Y, Heydarkhan-Hagvall S, Gekas C, Zhang R, Goldhaber JI, Mikkola HK, Plath K, MacLellan WR. Reprogrammed mouse fibroblasts differentiate into cells of the cardiovascular and hematopoietic lineages. Stem Cells. 2008;26:1537–1546. [PMC free article] [PubMed]
19. Narazaki G, Uosaki H, Teranishi M, Okita K, Kim B, Matsuoka S, Yamanaka S, Yamashita JK. Directed and systematic differentiation of cardiovascular cells from mouse induced pluripotent stem cells. Circulation. 2008;118:498–506. [PubMed]
20. Mauritz C, Schwanke K, Reppel M, Neef S, Katsirntaki K, Maier LS, Nguemo F, Menke S, Haustein M, Hescheler J, Hasenfuss G, Martin U. Generation of functional murine cardiac myocytes from induced pluripotent stem cells. Circulation. 2008;118:507–517. [PubMed]
21. Zhang J, Wilson GF, Soerens AG, Koonce CH, Yu J, Palecek SP, Thomson JA, Kamp TJ. Functional cardiomyocytes derived from human induced pluripotent stem cells. Circ Res. 2009;104:e30–e41. [PMC free article] [PubMed]
22. Nelson TJ, Martinez-Fernandez A, Yamada S, Mael AA, Terzic A, Ikeda Y. Promiscuous human stemness related factors induce interspecies pluripotent reprogramming. Clin Translation Sci. 2009;2:118–126. [PMC free article] [PubMed]
23. Hasegawa K, Nakamura T, Harvey M, Ikeda Y, Oberg A, Figini M, Canevari S, Hartmann LC, Peng KW. The use of a tropism-modified measles virus in folate receptor–targeted virotherapy of ovarian cancer. Clin Cancer Res. 2006;15:6170–6178. [PubMed]
24. Perez-Terzic C, Faustino RS, Boorsma BJ, Arrell DK, Niederländer NJ, Behfar A, Terzic A. Stem cells transform into a cardiac phenotype with remodeling of the nuclear transport machinery. Nat Clin Pract Cardiovasc Med. 2007;4 1:S68–S76. [PubMed]
25. Yamada S, Nelson TJ, Crespo-Diaz RJ, Perez-Terzic C, Liu XK, Miki T, Seino S, Behfar A, Terzic A. Embryonic stem cell therapy of heart failure in genetic cardiomyopathy. Stem Cells. 2008;26:2644–2653. [PMC free article] [PubMed]
26. Behfar A, Perez-Terzic C, Faustino RS, Arrell DK, Hodgson DM, Yamada S, Puceat M, Niederländer N, Alekseev AE, Zingman LV, Terzic A. Cardiopoietic programming of embryonic stem cells for tumor-free heart repair. J Exp Med. 2007;204:405–420. [PMC free article] [PubMed]
27. Behfar A, Zingman LV, Hodgson DM, Rauzier JM, Kane GC, Terzic A, Pucéat M. Stem cell differentiation requires a paracrine pathway in the heart. FASEB J. 2002;16:1558–1566. [PubMed]
28. Nelson TJ, Martinez-Fernandez A, Terzic A. KCNJ11 knockout morula reengineered by stem cell diploid aggregation. Phil Trans R Soc B. 2009;364:269–276. [PMC free article] [PubMed]
29. Nelson TJ, Faustino RS, Chiriac A, Crespo-Diaz R, Behfar A, Terzic A. CXCR4+/FLK-1+ biomarkers select a cardiopoietic lineage from embryonic stem cells. Stem Cells. 2008;26:1464–1474. [PubMed]
30. Nelson TJ, Chiriac A, Faustino RS, Crespo-Diaz RJ, Behfar A, Terzic A. Lineage specification of Flk-1+ progenitors is associated with divergent Sox7 expression in cardiopoiesis. Differentiation. 2009;77:248–255. [PMC free article] [PubMed]
31. Park IH, Arora N, Huo H, Maherali N, Ahfeldt T, Shimamura A, Lensch MW, Cowan C, Hochedlinger K, Daley GQ. Disease-specific induced pluripotent stem cells. Cell. 2008;134:877–886. [PMC free article] [PubMed]
32. Kim JB, Zaehres H, Wu G, Gentile L, Ko K, Sebastiano V, Araúzo-Bravo MJ, Ruau D, Han DW, Zenke M, Schöler HR. Pluripotent stem cells induced from adult neural stem cells by reprogramming with two factors. Nature. 2008;454:646–650. [PubMed]
33. Yamanaka S. Pluripotency and nuclear reprogramming. Philos Trans R Soc Lond B Biol Sci. 2008;363:2079–2087. [PMC free article] [PubMed]
34. Nelson TJ, Behfar A, Terzic A. Strategies for therapeutic repair: The “R3” regenerative medicine paradigm. Clin Translation Sci. 2008;1:168–171. [PMC free article] [PubMed]
35. Yang X, Smith SL, Tian XC, Lewin HA, Renard JP, Wakayama T. Nuclear reprogramming of cloned embryos and its implications for therapeutic cloning. Nat Genet. 2007;39:295–302. [PubMed]
36. Okita K, Nakagawa M, Hyenjong H, Ichisaka T, Yamanaka S. Generation of mouse induced pluripotent stem cells without viral vectors. Science. 2008;322:949–953. [PubMed]
37. Stadtfeld M, Nagaya M, Utikal J, Weir G, Hochedlinger K. Induced pluripotent stem cells generated without viral integration. Science. 2008;322:945–949. [PubMed]
38. Woltjen K, Michael IP, Mohseni P, Desai R, Mileikovsky M, Hämäläinen R, Cowling R, Wang W, Liu P, Gertsenstein M, Kaji K, Sung HK, Nagy A. piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature. 2009;458:766–770. [PubMed]
39. Anversa P, Leri A, Rota M, Hosoda T, Bearzi C, Urbanek K, Kajstura J, Bolli R. Stem cells, myocardial regeneration, and methodological artifacts. Stem Cells. 2007;25:589–601. [PubMed]
40. Gnecchi M, Zhang Z, Ni A, Dzau VJ. Paracrine mechanisms in adult stem cell signaling and therapy. Circ Res. 2008;103:1204–1219. [PMC free article] [PubMed]
41. Wu SM, Chien KR, Mummery C. Origins and fates of cardiovascular progenitor cells. Cell. 2008;132:537–543. [PMC free article] [PubMed]
42. Chien KR, Domian IJ, Parker KK. Cardiogenesis and the complex biology of regenerative cardiovascular medicine. Science. 2008;322:1494–1497. [PubMed]
43. Singla DK, Hacker TA, Ma L, Douglas PS, Sullivan R, Lyons GE, Kamp TJ. Transplantation of embryonic stem cells into the infarcted mouse heart: formation of multiple cell types. J Mol Cell Cardiol. 2006;40:195–200. [PubMed]
44. Hodgson DM, Behfar A, Zingman LV, Kane GC, Perez-Terzic C, Alekseev AE, Pucéat M, Terzic A. Stable benefit of embryonic stem cell therapy in myocardial infarction. Am J Physiol Heart Circ Physiol. 2004;287:H471–479. [PubMed]
45. Kolossov E, Bostani T, Roell W, Breitbach M, Pillekamp F, Nygren JM, Sasse P, Rubenchik O, Fries JW, Wenzel D, Geisen C, Xia Y, Lu Z, Duan Y, Kettenhofen R, Jovinge S, Bloch W, Bohlen H, Welz A, Hescheler J, Jacobsen SE, Fleischmann BK. Engraftment of engineered ES cell-derived cardiomyocytes but not BM cells restores contractile function to the infarcted myocardium. J Exp Med. 2006;203:2315–2327. [PMC free article] [PubMed]
46. Blomer U, Gruh I, Witschel H, Haverich A, Martin U. Shuttle of lentiviral vectors via transplanted cells in vivo. Gene Therapy. 2005;12:67–74. [PubMed]
47. Strang BL, Takeuchi Y, Relander T, Richter J, Bailey R, Sanders DA, Collins MK, Ikeda Y. Human immunodeficiency virus type 1 vectors with alphavirus envelope glycoproteins produced from stable packaging cells. J Virol. 2005;79:1765–1771. [PMC free article] [PubMed]
48. Passier R, van Laake LW, Mummery CL. Stem-cell-based therapy and lessons from the heart. Nature. 2008;453:322–329. [PubMed]
49. Nelson TJ, Behfar A, Terzic A. Stem cells: biologics for regeneration. Clin Pharmacol Ther. 2008;84:620–623. [PubMed]
50. Roell W, Lewalter T, Sasse P, Tallini YN, Choi BR, Breitbach M, Doran R, Becher UM, Hwang SM, Bostani T, von Maltzahn J, Hofmann A, Reining S, Eiberger B, Gabris B, Pfeifer A, Welz A, Willecke K, Salama G, Schrickel JW, Kotlikoff MI, Fleischmann BK. Engraftment of connexin 43-expressing cells prevents post-infarct arrhythmia. Nature. 2007;450:819–824. [PubMed]